このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Eiger BioPharmaceuticals 将来の成長

Future 基準チェック /06

We currently don't have sufficient analyst coverage to forecast growth and revenue for Eiger BioPharmaceuticals.

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	24.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Apr 06

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Mar 15

Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst

Dec 26

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Eiger BioPharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OTCPK:EIGR.Q - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	16	-75	-75	-75	N/A
9/30/2023	15	-87	-83	-83	N/A
6/30/2023	15	-96	-89	-89	N/A
3/31/2023	15	-97	-89	-89	N/A
12/31/2022	13	-97	-83	-83	N/A
9/30/2022	14	-93	-78	-78	N/A
6/30/2022	13	-89	-76	-76	N/A
3/31/2022	11	-86	-75	-75	N/A
12/31/2021	12	-34	-71	-71	N/A
9/30/2021	9	-31	-70	-70	N/A
6/30/2021	6	-24	-65	-65	N/A
3/31/2021	4	-21	-60	-60	N/A
12/31/2020	N/A	-65	-63	-63	N/A
9/30/2020	N/A	-63	-63	-63	N/A
6/30/2020	N/A	-66	-64	-63	N/A
3/31/2020	N/A	-68	-63	-62	N/A
12/31/2019	N/A	-70	-64	-64	N/A
9/30/2019	N/A	-70	-61	-61	N/A
6/30/2019	N/A	-68	-60	-60	N/A
3/31/2019	N/A	-61	-53	-53	N/A
12/31/2018	N/A	-52	-43	-43	N/A
9/30/2018	N/A	-47	-41	-41	N/A
6/30/2018	N/A	-39	-35	-35	N/A
3/31/2018	N/A	-40	-36	-36	N/A
12/31/2017	N/A	-42	-38	-38	N/A
9/30/2017	N/A	-44	N/A	-39	N/A
6/30/2017	N/A	-47	N/A	-38	N/A
3/31/2017	N/A	-49	N/A	-45	N/A
12/31/2016	N/A	-47	N/A	-38	N/A
9/30/2016	N/A	-41	N/A	-30	N/A
6/30/2016	N/A	-33	N/A	-25	N/A
3/31/2016	N/A	-22	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-9	N/A
9/30/2015	N/A	-7	N/A	-6	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if EIGR.Q's forecast earnings growth is above the savings rate (2.4%).

収益対市場: Insufficient data to determine if EIGR.Q's earnings are forecast to grow faster than the US market

高成長収益: Insufficient data to determine if EIGR.Q's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if EIGR.Q's revenue is forecast to grow faster than the US market.

高い収益成長: Insufficient data to determine if EIGR.Q's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if EIGR.Q's Return on Equity is forecast to be high in 3 years time

Eiger BioPharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 67% to US$30.00

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.45 loss

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

Recent updates

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index

The Nasdaq Stock Market LLC Determines Eiger Biopharmaceuticals' Common Stock to be Delisted from Nasdaq

Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy

Price target decreased by 67% to US$30.00

Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding No Longer Satisfies the $10 Million Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Global Market

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

No longer forecast to breakeven

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1)

New major risk - Share price stability

Consensus EPS estimates upgraded to US$1.45 loss

Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from Russell Small Cap Comp Value Index

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded

Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Eiger BioPharmaceuticals, Inc. Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Independent Chairman recently bought US$72k worth of stock

Eiger BioPharmaceuticals, Inc. Announces Sriram Ryali to Resign as Chief Financial Officer, Effective January 20, 2023

Forecast to breakeven in 2025

Key Executive recently bought US$128k worth of stock

RM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Eiger BioPharmaceuticals, Inc. Announces CEO Changes

Price target decreased to US$9.25

Eiger BioPharmaceuticals, Inc. Announces Topline Primary Week 48 Data from Its Landmark Phase 3 D-LIVR study

Forecast to breakeven in 2024

Pomerantz Law Firm Announces the Filing of a Class Action Against Eiger BioPharmaceuticals, Inc

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Third quarter 2022 earnings: EPS misses analyst expectations

Eiger BioPharmaceuticals, Inc. Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger Biopharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Eiger Biopharmaceuticals Inc. Announces European Commission (Ec) Has Granted Marketing Authorization for Zokinvy® (Lonafarnib

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals, Inc. Appoints Lisa Kelly-Croswell to Board of Directors

Eiger BioPharmaceuticals, Inc. Announces Results from Multiple Presentations at the European Association for the Study of the Liver International Liver Congress 2022

Eiger Biopharmaceuticals, Inc. Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries

Insufficient new directors

Eiger Biopharmaceuticals, Inc. Receives Positive Chmp Opinion for Zokinvy as A Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Consensus revenue estimates fall by 22%

Insufficient new directors

Price target increased to US$32.00

Eiger BioPharmaceuticals, Inc. Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program

Eiger Biopharmaceuticals, Inc. Announces New Executive Appointments

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Consensus forecasts updated

Price target increased to US$31.80

Consensus revenue estimates fall by 35%